Cargando…

Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?

International guidelines advocate the early introduction of inhaled corticosteroids (ICS) in all types of persistent asthma. Our study was undertaken to assess the effects of ICS on bronchial hyperresponsiveness (BHR) as a hallmark of inflammation, and to assess the symptoms, the use of rescue medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanković, Ivana, Pejčić, Tatjana, Milenković, Branislava, Jovanović, Dragana, Rančić, Milan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901055/
https://www.ncbi.nlm.nih.gov/pubmed/17619791
http://dx.doi.org/10.1100/tsw.2007.134
_version_ 1783314535017349120
author Stanković, Ivana
Pejčić, Tatjana
Milenković, Branislava
Jovanović, Dragana
Rančić, Milan
author_facet Stanković, Ivana
Pejčić, Tatjana
Milenković, Branislava
Jovanović, Dragana
Rančić, Milan
author_sort Stanković, Ivana
collection PubMed
description International guidelines advocate the early introduction of inhaled corticosteroids (ICS) in all types of persistent asthma. Our study was undertaken to assess the effects of ICS on bronchial hyperresponsiveness (BHR) as a hallmark of inflammation, and to assess the symptoms, the use of rescue medications, and the parameters of lung function in patients with mild intermittent asthma. The patients with intermittent asthma (n = 85) were randomly allocated to a treatment with ICS, beclomethasone dipropionate 250 μg/day and short-acting β2 agonists salbutamol as needed (Group A, n = 45) or to a treatment with only short-acting β2 agonists as needed (Group B, n = 40) during the 6-month treatment period. At the end of the study, in Group A, we found a statistically significant decrease of BHR (PD(20) 0.98 vs. 2.07) (p < 0.001), diurnal peak expiratory flow (PEF) variability (17.9 vs. 13.8) (p < 0.001), symptom scores (0.63 vs. 0.30) (p < 0.001), and used rescue medication (p < 0.001), while the parameters of lung function remained unchanged except for forced expiratory volume in 1 sec (FEV1), which had a statistically significant increase (3.58 vs. 3.66) (p < 0.001). In Group B, there was a statistically significant decrease of lung function parameters FEV1 (3.80 vs. 3.71) (p < 0.001), forced vital capacity (FVC) (4.43 vs. 4.37) (p < 0.001), FEV1/FVC (88.2 vs. 85.3) (p < 0.05), PEF (8.05 vs. 7.51) (p < 0.01), PEF variability (17.85 vs. 18.33) (p < 0.001), increased BHR (PD(20) 1.04 vs. 0.62) (p < 0.05), and symptom scores (0.46 vs. 0.62) (p < 0.01), as well as the use of rescue medication during the day (p < 0.001). Early introduction of low doses of ICS may be more beneficial than β2 agonists alone in patients with intermittent asthma.
format Online
Article
Text
id pubmed-5901055
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher TheScientificWorldJOURNAL
record_format MEDLINE/PubMed
spelling pubmed-59010552018-06-03 Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma? Stanković, Ivana Pejčić, Tatjana Milenković, Branislava Jovanović, Dragana Rančić, Milan ScientificWorldJournal Research Article International guidelines advocate the early introduction of inhaled corticosteroids (ICS) in all types of persistent asthma. Our study was undertaken to assess the effects of ICS on bronchial hyperresponsiveness (BHR) as a hallmark of inflammation, and to assess the symptoms, the use of rescue medications, and the parameters of lung function in patients with mild intermittent asthma. The patients with intermittent asthma (n = 85) were randomly allocated to a treatment with ICS, beclomethasone dipropionate 250 μg/day and short-acting β2 agonists salbutamol as needed (Group A, n = 45) or to a treatment with only short-acting β2 agonists as needed (Group B, n = 40) during the 6-month treatment period. At the end of the study, in Group A, we found a statistically significant decrease of BHR (PD(20) 0.98 vs. 2.07) (p < 0.001), diurnal peak expiratory flow (PEF) variability (17.9 vs. 13.8) (p < 0.001), symptom scores (0.63 vs. 0.30) (p < 0.001), and used rescue medication (p < 0.001), while the parameters of lung function remained unchanged except for forced expiratory volume in 1 sec (FEV1), which had a statistically significant increase (3.58 vs. 3.66) (p < 0.001). In Group B, there was a statistically significant decrease of lung function parameters FEV1 (3.80 vs. 3.71) (p < 0.001), forced vital capacity (FVC) (4.43 vs. 4.37) (p < 0.001), FEV1/FVC (88.2 vs. 85.3) (p < 0.05), PEF (8.05 vs. 7.51) (p < 0.01), PEF variability (17.85 vs. 18.33) (p < 0.001), increased BHR (PD(20) 1.04 vs. 0.62) (p < 0.05), and symptom scores (0.46 vs. 0.62) (p < 0.01), as well as the use of rescue medication during the day (p < 0.001). Early introduction of low doses of ICS may be more beneficial than β2 agonists alone in patients with intermittent asthma. TheScientificWorldJOURNAL 2007-07-03 /pmc/articles/PMC5901055/ /pubmed/17619791 http://dx.doi.org/10.1100/tsw.2007.134 Text en Copyright © 2007 Ivana Stankovic et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Stanković, Ivana
Pejčić, Tatjana
Milenković, Branislava
Jovanović, Dragana
Rančić, Milan
Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?
title Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?
title_full Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?
title_fullStr Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?
title_full_unstemmed Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?
title_short Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?
title_sort is there any point in a corticosteroid treatment of intermittent asthma?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901055/
https://www.ncbi.nlm.nih.gov/pubmed/17619791
http://dx.doi.org/10.1100/tsw.2007.134
work_keys_str_mv AT stankovicivana isthereanypointinacorticosteroidtreatmentofintermittentasthma
AT pejcictatjana isthereanypointinacorticosteroidtreatmentofintermittentasthma
AT milenkovicbranislava isthereanypointinacorticosteroidtreatmentofintermittentasthma
AT jovanovicdragana isthereanypointinacorticosteroidtreatmentofintermittentasthma
AT rancicmilan isthereanypointinacorticosteroidtreatmentofintermittentasthma